Roxana Ola1,2,3,4, Sandrine H Künzel1, Feng Zhang1, Gael Genet1, Raja Chakraborty1, Laurence Pibouin-Fragner5, Kathleen Martin1, William Sessa6, Alexandre Dubrac1, Anne Eichmann1,7,5. 1. Cardiovascular Research Center, Department of Internal Medicine (R.O., S.H.K., F.Z., G.G., R.C., K.M., A.D., A.E.), Yale University School of Medicine, New Haven, Connecticut. 2. Functional Genomics, Proteomics and Experimental Pathology Department, Prof. Dr. I. Chiricuta Oncology Institute, Cluj-Napoca, Romania (R.O.). 3. Research Center for Functional Genomics, Biomedicine and Translational Medicine, I. Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania (R.O.). 4. Department of Basic, Preventive and Clinical Science, University of Transylvania, Brasov, Romania (R.O.). 5. Inserm U970, Paris Cardiovascular Research Center, Paris, France (L.P-F., A.E.). 6. Vascular Biology and Therapeutics Program, Department of Pharmacology (W.S.), Yale University School of Medicine, New Haven, Connecticut. 7. Department of Cellular and Molecular Physiology (A.E.), Yale University School of Medicine, New Haven, Connecticut.
Abstract
BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder that causes arteriovenous malformations (AVMs). Mutations in the genes encoding Endoglin ( ENG) and activin-receptor-like kinase 1 ( AVCRL1 encoding ALK1) cause HHT type 1 and 2, respectively. Mutations in the SMAD4 gene are present in families with juvenile polyposis-HHT syndrome that involves AVMs. SMAD4 is a downstream effector of transforming growth factor-β (TGFβ)/bone morphogenetic protein (BMP) family ligands that signal via activin-like kinase receptors (ALKs). Ligand-neutralizing antibodies or inducible, endothelial-specific Alk1 deletion induce AVMs in mouse models as a result of increased PI3K (phosphatidylinositol 3-kinase)/AKT (protein kinase B) signaling. Here we addressed if SMAD4 was required for BMP9-ALK1 effects on PI3K/AKT pathway activation. METHODS: The authors generated tamoxifen-inducible, postnatal, endothelial-specific Smad4 mutant mice ( Smad4iΔEC). RESULTS: We found that loss of endothelial Smad4 resulted in AVM formation and lethality. AVMs formed in regions with high blood flow in developing retinas and other tissues. Mechanistically, BMP9 signaling antagonized flow-induced AKT activation in an ALK1- and SMAD4-dependent manner. Smad4iΔEC endothelial cells in AVMs displayed increased PI3K/AKT signaling, and pharmacological PI3K inhibitors or endothelial Akt1 deletion both rescued AVM formation in Smad4iΔEC mice. BMP9-induced SMAD4 inhibited casein kinase 2 ( CK2) transcription, in turn limiting PTEN phosphorylation and AKT activation. Consequently, CK2 inhibition prevented AVM formation in Smad4iΔEC mice. CONCLUSIONS: Our study reveals SMAD4 as an essential effector of BMP9-10/ALK1 signaling that affects AVM pathogenesis via regulation of CK2 expression and PI3K/AKT1 activation.
BACKGROUND:Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder that causes arteriovenous malformations (AVMs). Mutations in the genes encoding Endoglin ( ENG) and activin-receptor-like kinase 1 ( AVCRL1 encoding ALK1) cause HHT type 1 and 2, respectively. Mutations in the SMAD4 gene are present in families with juvenile polyposis-HHT syndrome that involves AVMs. SMAD4 is a downstream effector of transforming growth factor-β (TGFβ)/bone morphogenetic protein (BMP) family ligands that signal via activin-like kinase receptors (ALKs). Ligand-neutralizing antibodies or inducible, endothelial-specific Alk1 deletion induce AVMs in mouse models as a result of increased PI3K (phosphatidylinositol 3-kinase)/AKT (protein kinase B) signaling. Here we addressed if SMAD4 was required for BMP9-ALK1 effects on PI3K/AKT pathway activation. METHODS: The authors generated tamoxifen-inducible, postnatal, endothelial-specific Smad4 mutant mice ( Smad4iΔEC). RESULTS: We found that loss of endothelial Smad4 resulted in AVM formation and lethality. AVMs formed in regions with high blood flow in developing retinas and other tissues. Mechanistically, BMP9 signaling antagonized flow-induced AKT activation in an ALK1- and SMAD4-dependent manner. Smad4iΔEC endothelial cells in AVMs displayed increased PI3K/AKT signaling, and pharmacological PI3K inhibitors or endothelial Akt1 deletion both rescued AVM formation in Smad4iΔEC mice. BMP9-induced SMAD4 inhibited casein kinase 2 ( CK2) transcription, in turn limiting PTENphosphorylation and AKT activation. Consequently, CK2 inhibition prevented AVM formation in Smad4iΔEC mice. CONCLUSIONS: Our study reveals SMAD4 as an essential effector of BMP9-10/ALK1 signaling that affects AVM pathogenesis via regulation of CK2 expression and PI3K/AKT1 activation.
Authors: G Di Maira; M Salvi; G Arrigoni; O Marin; S Sarno; F Brustolon; L A Pinna; M Ruzzene Journal: Cell Death Differ Date: 2005-06 Impact factor: 15.828
Authors: Mara E Pitulescu; Inga Schmidt; Benedetto Daniele Giaimo; Tobiah Antoine; Frank Berkenfeld; Francesca Ferrante; Hongryeol Park; Manuel Ehling; Daniel Biljes; Susana F Rocha; Urs H Langen; Martin Stehling; Takashi Nagasawa; Napoleone Ferrara; Tilman Borggrefe; Ralf H Adams Journal: Nat Cell Biol Date: 2017-07-17 Impact factor: 28.824
Authors: Paola Corti; Sarah Young; Chia-Yuan Chen; Michael J Patrick; Elizabeth R Rochon; Kerem Pekkan; Beth L Roman Journal: Development Date: 2011-03-09 Impact factor: 6.868
Authors: Heon-Woo Lee; Diana C Chong; Roxana Ola; William P Dunworth; Stryder Meadows; Jun Ka; Vesa M Kaartinen; Yibing Qyang; Ondine Cleaver; Victoria L Bautch; Anne Eichmann; Suk-Won Jin Journal: Arterioscler Thromb Vasc Biol Date: 2017-02-23 Impact factor: 8.311
Authors: D W Johnson; J N Berg; M A Baldwin; C J Gallione; I Marondel; S J Yoon; T T Stenzel; M Speer; M A Pericak-Vance; A Diamond; A E Guttmacher; C E Jackson; L Attisano; R Kucherlapati; M E Porteous; D A Marchuk Journal: Nat Genet Date: 1996-06 Impact factor: 38.330
Authors: Nicolas Baeyens; Bruno Larrivée; Roxana Ola; Brielle Hayward-Piatkowskyi; Alexandre Dubrac; Billy Huang; Tyler D Ross; Brian G Coon; Elizabeth Min; Maya Tsarfati; Haibin Tong; Anne Eichmann; Martin A Schwartz Journal: J Cell Biol Date: 2016-09-19 Impact factor: 10.539
Authors: Daniel A Snellings; Carol J Gallione; Dewi S Clark; Nicholas T Vozoris; Marie E Faughnan; Douglas A Marchuk Journal: Am J Hum Genet Date: 2019-10-17 Impact factor: 11.025
Authors: Yong Hwan Kim; Phuong-Nhung Vu; Se-Woon Choe; Chang-Jin Jeon; Helen M Arthur; Calvin P H Vary; Young Jae Lee; S Paul Oh Journal: Circ Res Date: 2020-07-31 Impact factor: 17.367